Mon Jan 27 04:30:00 UTC 2025: ## Laurus Labs Soars on Strong Q3 Results

**Mumbai, January 24, 2025** – Shares of Laurus Labs Ltd., a mid-cap pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) and Intermediates, surged 4.5 percent to close at Rs 611.50 on Friday. The jump follows the release of the company’s strong Q3FY24-25 results, which showed a remarkable 259 percent year-on-year increase in net profit, reaching Rs 90.61 crore.

Revenue also saw significant growth, climbing 18.4 percent year-on-year to Rs 1,415.05 crore. This represents a 15.6 percent quarter-on-quarter increase from Rs 1,223.70 crore in Q2FY25. The company’s diverse business segments contributed to this success, with the CDMO, API, and FDF divisions accounting for 28.2 percent, 37.5 percent, and 30.8 percent of total revenue respectively.

Laurus Labs’ robust performance is further bolstered by its significant investments in research and development. R&D expenditure increased by 25 percent year-on-year, now representing 5.4 percent of H1FY25 sales. The company boasts five state-of-the-art R&D labs in India and a pipeline of 62 products targeting high-growth markets. Furthermore, Laurus Labs successfully completed 76 quality audits without any critical findings.

The company’s market capitalization currently stands at Rs 32,969.59 crore. Looking ahead, Laurus Labs plans to allocate Rs 2,000 crore in capital expenditure to fuel future growth and expand its operations across its 12 manufacturing sites. The company operates globally and holds a leadership position in certain API markets.

**Disclaimer:** *This news article is based on publicly available information. Investing in stocks involves significant risk. Consult a financial advisor before making any investment decisions.*

Read More